期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Advantage of autologous blood transfusion in surgery for hepatocellular carcinoma 被引量:8
1
作者 Yoshito Tomimaru Hidetoshi Eguchi +7 位作者 Shigeru Marubashi Hiroshi Wada Shogo Kobayashi Masahiro Tanemura Koji Umeshita Yuichiro Doki Masaki Mori Hiroaki Nagano 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第32期3709-3715,共7页
AIM: To evaluate the significance of autologous blood transfusion (AT) in reducing homologous blood transfusion (HT) in surgery for hepatocellular carcinoma (HCC). METHODS: The proportion of patients who received HT w... AIM: To evaluate the significance of autologous blood transfusion (AT) in reducing homologous blood transfusion (HT) in surgery for hepatocellular carcinoma (HCC). METHODS: The proportion of patients who received HT was compared between two groups determined by the time of AT introduction; period A (1991-1994, n = 93) and period B (1995-2000, n = 201). Multivariate logistic regression analysis was performed in order to identify independent significant predictors of the need for HT. We also investigated the impact of AT and HT on long-term postoperative outcome after curative surgery for HCC. RESULTS: The proportion of patients with HT was significantly lower in period B than period A (18.9% vs 60.2%, P < 0.0001). Multivariate logistic regression analysis identified AT administration as a significant independent predictor of the need for HT (P < 0.0001). Disease-free survival in patients with AT was comparable to that without any transfusion. Multivariate analysis identified HT administration as an independent significant factor for poorer disease-free survival (P = 0.0380). CONCLUSION: AT administration significantly decreased the need for HT. Considering the postoperative survival disadvantage of HT, AT administration could improve the long-term outcome of HCC patients. 展开更多
关键词 Hepatocellular carcinoma SURGERY Autologous blood transfusion homologous blood transfusion
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部